A simple, precise and accurate reversed-phase liquid chromatographic method has been developed for the simultaneous estimation of Drospirenone and Ethinylestradiol in tablet formulation. The chromatographic separation was achieved on a XTerra Phenyl 150 x 4.6 mm 5µ analytical column. A mixture of water and acetonitrile in the ratio of 35:65 v/v was used as the mobile phase. The flow rate of the mobile phase was 1.0 ml/min. UV detector wavelength 260 nm was used for the quantification of Drospirenone and FLD 285 nm Excitation, 310 nm Emission for Ethinylestradiol. The limit of detection and quantification for Drospirenone was 0.02 and 0.05ug/mL and for Ethinylestradiol 0.21 and 0.45 ng/mL respectively. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantification, accuracy, precision and robustness. A method was found suitable for quality control analysis of Drospirenone and Ethinyl estradiol in tablet dosage form.
Introduction
Drospirenone is a synthetic progestin that is used in birth control, chemically (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1, 3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13-dimethylspiro-[17H-dicyclopropa-6,7:15,16] cyclopenta
[a]phenanthrene-17,2'(5H)-furan]-3,5'(2H)-dione. Ethinylestradiol (USP2007) is chemically 19-Nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol is a derivative of estradiol. Ethinyl estradiol is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills. For the prevention of pregnancy 3 mg Drospirenone and 30 mcg Ethinylestradiol per tablet is used as an oral contraceptive pill in women. So far, some liquid chromatographic procedures have been described for the determination of Drospirenone in formulation (Gogineni et al., 2005) . LC-MS method for the Determination of Drospirenone in Human plasma (Bhaumik et al., 2008 ) . UV spectrophotometic and HPLC method for the simultaneous estimation of Ethinylestradiol in combination with different Drug substances ( Sohrabi et al., 2010; Nguyen 1990; Prabhakar et al., 1999; Philip et al., 2010 ) . LC-MS method for the determination of Ethinylestradiol in combination with another drug substances ( Eduardo et al., 1987; Liu et al., 1987) . Mass Spectrometry method for the determination of Ethinylestradiol (Zhang et al., 2010) . To the best of our knowledge all above analytical methods are used only for the quantification of Drospirenone and Ethinylestradiol as a single component, or in combination with another drug substance. The proposed work has a precise and accurate isocratic reversed-phase HPLC method for the simultaneous determination of Drospirenone and Ethinylestradiol using combine UV and Fluorescence Detector. 
Material and methods

Chemicals and Reagents
Drospirenone and Ethinylestradiol working standards were obtained from Sir Sayyed College Roshan Gate, Aurangabad, M.S., India. Acetonitrile (HPLC grade) was from Merck Fine Chemicals (Mumbai, India). 0.45-um nylon filter was obtained from Advanced Micro Devices Pvt Ltd. The combination product of Drospirenone and Ethinylestradiol having the label claim Drospirenone 3 mg and Ethinylestradiol 3 mcg tablet (Hervote) Torrent Pharmaceuticals Ltd. was purchased from the Indian market. Double distilled water was used throughout the experiment. Other chemicals used are of analytical or LC grade.
Chromatographic conditions
The chromatographic system used was a Dionex ultimate 3000 comprised of degasser, quaternary pump, auto injector, column compartment, UV and Fluorescence detectors and System control. Data collection and data processing were accomplished using Chromeleon software. The separation of Drospirenone 3mg and Ethinylestradiol 3 mcg was achieved on XTerra Phenyl 150 x 4.6mm 5µ column. Isocratic mode was selected by using the Mixture of water:acetonitrile (35:65 v/v). Flow rate of mobile phase was 1.0 ml/min, injection volume was 10µL; the UV detector was connected serially after the fluorescence detector. Fluorescence detector was set at 285 nm Excitation, 310 nm Emission for Ethinylestradiol. UV detector was set at 260 nm for Drospirenone. Column oven temperature was set at 25 0 C.
Fig 2. A Typical HPLC Chromatogram of Test solution
Solution Preparation 2.3.1 Preparation of Standard Solution
The assay standard stock solution was prepared by dissolving working standard in a diluent, followed by second dilution in diluent to get desired Standard concentration of Drospirenone 120 µg/mL and Ethinylestradiol 1.2 µg/mL.
Preparation of Sample Solution
Finely crush not less than 20 tablets. Accurately weigh and transfer the tablet equivalent to about 60 mg of Drospirenone and 6 mg of Ethinylestradiol into a 500 mL volumetric flask. Add about 300 mL of diluent and sonicated for 30 minutes with intermittent shaking. Dilute to volume with diluent and mix. Filter the solution through 0.45µ Nylon filter and collect the sample after discarding 5 mL of the filtrate.
Experimental
3.1Method Validation
As per ICH Guideline (Q2A(R1)) method validation has been performed for the parameters such as specificity, linearity, precision, accuracy, limit of detection (LOD), limit of quantification (LOQ), robustness and system suitability.
3.1.1Specificity
Specificity is the ability to assess unequivocally analyte in the presence of components that may be expected to be present, such as impurities, degradation products, matrix components etc. The specificity of the drospirenone peak was checked by peak purity test, were peak purity analysis was done by photodiode array detector. The purity angle was less than the purity threshold for drospirenone peak. This shows that the drospirenone peak was pure and excipients in the formulation do not interfere with drospirenone analyte. The specificity of the Ethinylestradiol peak has been checked by injecting blank and placebo samples and it was observed that there is no interferance at the retention time of Ethinylestradiol peak.
System Suitability
System performance was measured by calculating therotical plates, peak asymmetry and % RSD of six replicate injections of standard solution and is shown in table 1. 
Limit of detection (LOD) and limit of quantitation (LOQ)
The LOD and LOQ for Drospirenone and Ethinylestradiol was determined by signal to-noise ratio of 3:1 and 10:1 respectively by injecting a series of dilute solutions with known concentrations. The LOD and LOQ are as shown in Table No . 2.
Linearity
The linearity of Drospirenone and Ethinylestradiol was determined at five concentration levels, ranging from 50 to 150% of test concentrations such as 60 µg/mL to 180 µg/mL for Drospirenone and 0.6 µg/mL to 1.8 µg/mL for Ethinylestradiol. Linearity results are reported in Table No . 2. 3.1.6 Robustness The robustness is capacity of the method to remain unaffected by small, but deliberate changes in chromatographic conditions. Robustness was studied by testing the influence of small changes in column temperature (25 0 C)( +5 o C), change in flow rate ( +5%) and Changes in organic composition (+ 5%).
Stability in Solution and in the Mobile Phase
No significant changes in the assay of drug product were observed during solution stability and mobile phase stability experiments. The results from solution stability and mobile phase stability experiments confirmed that standard solution and sample solution was stable up to 24 h. and the mobile phase was stable up to 48h.
Results and Discussion
Method Development and Optimization
Effect of the Organic Modifier
The main objective of the development of a HPLC method for determination of Drospirenone and Ethinylestradiol in Tablet dosage form was that the method should be able to determine assays of both drugs in a single run with the run time <10 min. The method development was initiated with a mixture of water and methanol. Different proportions of water and methanol have been used, but the Drospirenone peak is not eluted with expected retention time. The methanol is replaced with acetonitrile as an organic modifier to get the expected retention time for both; the analytes also meets the expected system suitability criteria.
Effect of Stationary Phase.
Reversed-phase columns are silica based bonded phases. C8 and C18 are the type of bonded phases most frequently used, so different brands of C8-C18 type of HPLC columns have been used. Initial method development is started with the C8 column where peak shape of the Drospirenone peak is not proper; also both the ethinylestradiol and Drospirenone peaks are closely eluted with each other. The C18 column is also unable to give better separation between the ethinylestradiol and Drospirenone peak. To improve on that front phenyl columns have been tried. Substituted aromatic ring in the phenyl column gives better selectivity and good separation between Ethinylestradiol and Drospirenone peaks due to π π interaction between analyte and phenyl group on the column. Endcaping of the free silanols in the phenyl column is also helpful for the improvement of peak shape for the Drospirenone peak. XTerra Phenyl 150 x 4.6 mm 5µ column will fulfill all the system suitability requirements. Ethinylestradiol is a fluorescence active compound, whereas Drospirenone is an UV active compound, so serial connection of FLD and UV Detector has been used for the simultaneous determination of both the compounds. The flow rate of the mobile phase was adjusted to obtain the expected retention time of the analyte. 
Conclusion
A simple, specific liquid chromatographic method was developed for the quantification of Drospirenone and Ethinylestradiol simultaneously. This method is found to be specific, precise, accurate and linear for the detection and quantification of Drospirenone and Ethinylestradiol and useful for routine quality control analysis.
